Vigilant Capital Management LLC lowered its stake in shares of AstraZeneca plc (NYSE:AZN) by 0.8% during the 4th quarter, Holdings Channel.com reports. The fund owned 316,587 shares of the company’s stock after selling 2,525 shares during the quarter. AstraZeneca makes up approximately 1.8% of Vigilant Capital Management LLC’s portfolio, making the stock its 28th largest holding. Vigilant Capital Management LLC’s holdings in AstraZeneca were worth $15,785,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently bought and sold shares of AZN. Prime Capital Investment Advisors LLC bought a new stake in AstraZeneca during the third quarter valued at approximately $34,000. Allred Capital Management LLC purchased a new stake in shares of AstraZeneca in the 4th quarter worth $43,000. Venturi Wealth Management LLC purchased a new stake in shares of AstraZeneca in the 3rd quarter worth $46,000. Simon Quick Advisors LLC raised its holdings in AstraZeneca by 1,515.0% in the 4th quarter. Simon Quick Advisors LLC now owns 969 shares of the company’s stock worth $48,000 after purchasing an additional 909 shares during the period. Finally, Resources Management Corp CT ADV bought a new position in AstraZeneca in the 3rd quarter worth $49,000. Institutional investors and hedge funds own 17.44% of the company’s stock.
AZN has been the subject of a number of analyst reports. Zacks Investment Research cut AstraZeneca from a “strong-buy” rating to a “hold” rating and set a $49.00 price target for the company. in a research report on Thursday, October 3rd. Svb Leerink began coverage on AstraZeneca in a research report on Friday, November 22nd. They set an “outperform” rating on the stock. Cowen reaffirmed an “outperform” rating and set a $55.00 price objective (up from $48.00) on shares of AstraZeneca in a research report on Monday, December 2nd. Leerink Swann started coverage on AstraZeneca in a research note on Friday, November 22nd. They set an “outperform” rating and a $57.00 price objective for the company. Finally, Liberum Capital reissued a “hold” rating on shares of AstraZeneca in a report on Thursday, October 24th. Five analysts have rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company’s stock. AstraZeneca has a consensus rating of “Hold” and a consensus price target of $50.35.
AstraZeneca (NYSE:AZN) last announced its quarterly earnings results on Thursday, October 24th. The company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.45 by $0.05. AstraZeneca had a net margin of 8.42% and a return on equity of 38.63%. The business had revenue of $6.13 billion for the quarter, compared to analysts’ expectations of $6.07 billion. During the same quarter in the previous year, the company earned $0.71 EPS. The business’s quarterly revenue was up 14.8% compared to the same quarter last year. Equities analysts expect that AstraZeneca plc will post 1.81 EPS for the current year.
About AstraZeneca
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: P/E Growth (PEG)
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
